Reducing Involuntary Movements in Participants With Tardive Dyskinesia
Public ClinicalTrials.gov record NCT02198794. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.
Study identification
- NCT ID
- NCT02198794
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 343 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2014 (Actual)
- Primary completion
- Dec 6, 2019 (Actual)
- Completion
- Dec 14, 2020 (Actual)
- Last update posted
- Apr 1, 2022
2014 – 2020
United States locations
- U.S. sites
- 44
- U.S. states
- 20
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 145 | Tuscaloosa | Alabama | 35404 | — |
| Teva Investigational Site 107 | Anaheim | California | 92804 | — |
| Teva Investigational Site 108 | Anaheim | California | 92805 | — |
| Teva Investigational Site 123 | Glendale | California | 91206 | — |
| Teva Investigational Site 160 | Irvine | California | 92614 | — |
| Teva Investigational Site 176 | Loma Linda | California | 92354 | — |
| Teva Investigational Site 121 | Los Angeles | California | 90033 | — |
| Teva Investigational Site 147 | Los Angeles | California | 90095-1769 | — |
| Teva Investigational Site 174 | Norwalk | California | 90650 | — |
| Teva Investigational Site 130 | Oceanside | California | 92056 | — |
| Teva Investigational Site 102 | Orange | California | 92868 | — |
| Teva Investigational Site 104 | San Bernardino | California | 92408 | — |
| Teva Investigational Site 110 | San Diego | California | 92108 | — |
| Teva Investigational Site 169 | San Rafael | California | 94901 | — |
| Teva Investigational Site 129 | Englewood | Colorado | 80113 | — |
| Teva Investigational Site 139 | New Haven | Connecticut | 06519 | — |
| Teva Investigational Site 156 | Washington D.C. | District of Columbia | 20007 | — |
| Teva Investigational Site 157 | Boca Raton | Florida | 33486 | — |
| Teva Investigational Site 117 | Gainesville | Florida | 32607 | — |
| Teva Investigational Site 150 | Lake City | Florida | 32025 | — |
| Teva Investigational Site 153 | Miami | Florida | 33135 | — |
| Teva Investigational Site 162 | Miami | Florida | 33165 | — |
| Teva Investigational Site 112 | Orlando | Florida | 32803 | — |
| Teva Investigational Site 144 | Port Charlotte | Florida | 33980 | — |
| Teva Investigational Site 155 | Augusta | Georgia | 30912 | — |
| Teva Investigational Site 165 | Decatur | Georgia | 30033 | — |
| Teva Investigational Site 131 | Chicago | Illinois | 60611 | — |
| Teva Investigational Site 154 | Baltimore | Maryland | 21287 | — |
| Teva Investigational Site 101 | Glen Burnie | Maryland | 21061 | — |
| Teva Investigational Site 118 | Creve Coeur | Missouri | 63141 | — |
| Teva Investigational Site 142 | Kansas City | Missouri | 64108 | — |
| Teva Investigational Site 175 | St Louis | Missouri | 63104 | — |
| Teva Investigational Site 161 | St Louis | Missouri | 63109 | — |
| Teva Investigational Site 178 | Lincoln | Nebraska | 68526-9467 | — |
| Teva Investigational Site 128 | Albuquerque | New Mexico | 87106 | — |
| Teva Investigational Site 146 | Raleigh | North Carolina | 27610 | — |
| Teva Investigational Site 114 | Garfield Heights | Ohio | 44125 | — |
| Teva Investigational Site 133 | Charleston | South Carolina | 29425 | — |
| Teva Investigational Site 149 | Memphis | Tennessee | 38163 | — |
| Teva Investigational Site 151 | Fort Worth | Texas | 76104 | — |
| Teva Investigational Site 115 | Salt Lake City | Utah | 84105 | — |
| Teva Investigational Site 141 | Salt Lake City | Utah | 84108 | — |
| Teva Investigational Site 167 | Richland | Washington | 99352 | — |
| Teva Investigational Site 166 | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02198794, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02198794 live on ClinicalTrials.gov.